Range Impact (RNGE) 10-Q2019 Q1 Quarterly report

Filed: 13 Aug 19, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absorbed, absorption, accelerate, agent, animal, attach, binding, bioactive, blood, borrowing, broader, calendar, cannabidivarin, cannabinol, CBDV, CBN, CEO, characterized, clause, cleave, commonly, compatibility, complement, complementary, complied, compound, concentrated, constipation, corroborated, create, created, criteria, cumulative, damage, debilitating, decided, digestive, discretion, distinct, diversified, diversify, diversifying, Division, document, documentation, documented, dose, drink, duration, employed, equally, equipment, expertise, family, favorable, fewer, fill, flexible, flow, functional, glucose, greatly, growth, hand, hinder, holder, hydrolase, hypothetical, iii, implicit, important, inactive, incremental, IND, inflamed, inflection, ingestion, intact, intensive, irreversible, issuable, iv, kit, lead, learned, letter, leverage, Los, low, managerial, marketplace, mechanism, method, methodology, microbiota, minimizing, molecule, opportunistically, opportunity, optimal, overactive, partnership, percentage, pharmacokinetic, physiologically, point, polar, preclinicalin, prerequisite, prescribed, profile, promising, rapid, readily, remove, represent, represented, requisite, resale, respond, ROU, secreted, securing, simplify, single, solubility, soluble, stable, stage, stomach, stream, suffering, supplemental, surgery, testimony, tissue, transform, transit, understanding, unique, unmet, unpredictable, unrealized, unwanted, upper, virtually, vitroandin, vivo, Washington, water, whichever, written

Removed: abbreviated, achieved, acute, adjusted, administer, adult, advanced, advantage, advisory, aim, amortization, amplify, analyzed, anorexia, appetite, apply, approve, approved, assessing, Australia, authorized, autism, avoid, avoided, biotechnology, bloodstream, brain, brand, Brazil, breastfeeding, broad, Canada, cancer, cannaboside, case, CDAC, children, China, colonize, colorectal, commitment, comprehensive, computing, continued, contract, conventional, Cooperation, dedicated, deliver, delivered, demonstrated, Department, differentiated, discontinue, discount, dronabinol, earliest, earn, efficient, efficiently, eliminating, employee, employment, enforce, entry, Europe, event, eventual, examine, exclude, exclusive, Expedited, expensive, experienced, expired, extend, extensive, extensively, familiarity, feature, February, Food, forfeited, forfeiture, freestanding, generic, GI, granted, greater, gut, handling, healthy, Hedging, higher, history, hold, improvement, independently, indexed, induce, inducing, infringing, initiation, integral, internally, international, internationally, intoxication, investigated, involving, issuer, Japan, Justice, lapse, larger, licensing, line, MARINOLTM, mediating, mental, Mexico, microbiome, month, narcotic, nausea, NBS, neural, neurological, observational, older, opiate, opioid, organizational, overnight, Panel, patient, pediatric, periodically, permeability, pipeline, power, pregnant, preventing, prevention, primary, professional, profit, prosecution, prospective, protect, protection, psychoactivity, quickly, ranging, ratably, reached, receive, recipient, recommended, reduction, refractory, regional, registered, reliable, relief, relieve, repair, repayment, repeatedly, requiring, researching, restriction, revised, round, satisfaction, satisfied, schedule, selling, separately, September, set, settled, site, sleep, spectrum, spend, sponsor, straight, strike, strongly, studied, study, submitted, substitution, successful, suite, supporting, targeting, termination, therapy, titled, today, tolerability, treat, treating, Treaty, TRPV, ultimately, unlocking, unvested, vanilloid, verification, version, vest, vested, visceral, vomiting, widespread, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RNGE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Michael Cavanaugh, the Chief Executive Officer of Vitality Biopharma, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2019, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Michael Cavanaugh
Michael Cavanaugh
Chief Executive Officer
(Principal Executive Officer)

Date: August 13, 2019

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Richard McKilligan, the Chief Financial Officer of Vitality Biopharma, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2019, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

/s/ Richard McKilligan
Richard McKilligan
Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: August 13, 2019

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.